Search for a command to run...
Background. Hodgkin lymphoma is one of the highly curable types of cancer, but patients with advanced stages remain at risk of early progression and late chemotherapy effects. Aim. To evaluate the efficacy of first-line treatment for patients with newly diagnosed Hodgkin lymphoma in the Republic of Sakha (Yakutia). Materials and methods. We provided a retrospective analysis of 33 patients (17 women and 16 men, median age 42) with newly diagnosed Hodgkin lymphoma, who were treated in 2019–2024 (follow up to 01.06.2025). In the first-line treatment, depending on the stage and prognostic group, the following regimens were used: ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine), BEACOPP-esc, BEACOPP-14 (cyclophosphamide + doxorubicin + etoposide + dacarbazine + bleomycin + vincristine + prednisolone), BV-AVD (brentuximab vedotin + doxorubicin + vinblastine + dacarbazine) and IVDG (idarubicin + vinblastine + dacarbazine + gemcitabine). Statistical analysis performed using programs StatTech v.4.8.5 и R v.4.4.1. Results. Complete remission was achieved in 27 (87.1 %). Early relapse and progression were observed in 3 (9.7 %) patients. In patients with early stage 3-year overall survival and progression-free survival were 100 %, in advanced stage – 3-year overall survival – 95 %, progression free survival – 79.7 %. The most common side effects were grade 4 neutropenia in patients treated with BEACOPP-14 / esc (75.0–85.7 %) and peripheral polyneuropathy in patients treated with BV-AVD (45.5 %) which was in most cases reversible. There were no cases of refractoriness and relapse in patients, treated with BV-AVD at the time of analysis. Conclusion. Results of this study confirm the efficacy of modern chemotherapy regimens and compatible with the results of other large international studies. However, limited acceptance to PET-CT makes it difficult to realize risk-adapted protocols and optimization of treatment intensity. Long-term efficacy assessment requires additional studies with longer follow-up periods in larger population.